Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Ironwood closes $175mm debt offering

24 Jan 2013

Executive Summary

Ironwood Pharmaceuticals Inc. has sold $175mm of its Linaclotide PhaRMA 11% notes due on or before June 15, 2024 to 18 institutional investors. Proceeds will fund continued development of the company’s compounds for conditions including anxiety, respiratory, and cardiovascular diseases, and will also be put towards commercialization activities for Ironwood’s Linzess (linaclotide), which is marketed for constipation-predominant irritable bowel syndrome and chronic idiopathic constipation. Morgan Stanley was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By